Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...
The International Research Centre on Artificial Intelligence (IRCAI), an organization under the auspices of UNESCO, in collaboration with Amazon Web Services, Inc. (AWS), today announced the selection ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...
The company’s shares closed yesterday at $13.07. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Tectonic Therapeutic, and Gilead Sciences. According to TipRanks, Van ...
Democratic Party leaders and their donors bear responsibility for the increasingly widespread view of trans rights as ...
Roche Holding AG Akt 0.07% CHF227.85B Roche Holding AG-0.25% CHF227.85B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback